TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02058823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
Study: NCT01256177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate (SEROQUEL) Extended Release
Description: Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
Study: NCT01256177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
Study: NCT02587611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elemental liquid diet
Description: This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard semi-solid diet
Description: This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
Study: NCT03928197

Intervention type: DEVICE
Group type: OTHER
Intervention: Inbody S10
Description: Bio-electrical impedance measurement every 5 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: Inbody S10
Description: Bio-electrical impedance measurement every 5 minutes
Study: NCT02493569

Intervention type: PROCEDURE
Intervention: The radical mastectomy of breast cancer
Description: The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
Study: NCT01111305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reslizumab
Study: NCT03928197

Intervention type: DEVICE
Group type: OTHER
Intervention: Tape measurements
Description: Every 5 minutes, circumference of every leg is measured using a tape measure
Study: NCT01111305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diethylcarbamazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05752929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: correction scheme with Rapid Acting Insulin Analogs according with the Umpierrez sensitive correction scheme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: correction scheme with Rapid Acting Insulin Analogs according with the Davidson correction scheme
Study: NCT00962845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
Study: NCT02789657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
Study: NCT03928197

Intervention type: DEVICE
Group type: OTHER
Intervention: Tape measurements
Description: Every 5 minutes, circumference of every leg is measured using a tape measure

Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouchTMNIBP, Vivisol, Belgium
Description: Continous measurement of blood pressure, heart rate and saturation
Study: NCT00811213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 200 Auto Series with SensAwake
Description: Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
Study: NCT02789657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
Study: NCT02806076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch RFA arm
Description: No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
Study: NCT00811213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SleepStyle 200 Auto Series with out SensAwake
Description: Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
Study: NCT00983567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: teen web
Description: Min web

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teen web
Description: Min web
Study: NCT01679002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT01947062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cisplatin & etoposide
Description: Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Cisplatin & etoposide along with oral cyclophosphamide
Description: Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
Study: NCT02247648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Description: Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients from control group received a shame tramadol pill on day one, two, and 3
Study: NCT02284425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00473122

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed-Immediate Breast Reconstruction
Description: Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
Study: NCT03317327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a humanized antibody used in cancer immunotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
Study: NCT04315584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT Scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT Scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging Scan
Description: Undergo a multiparametric MRI scan
Study: NCT01679002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Study: NCT01728779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation (SBRT)
Description: 15 Gy dose (per lesion site) of SBRT will be administered
Study: NCT04315584

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: IV (intravenous) administration of radiotracer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorodopa
Description: IV (intravenous) administration of radiotracer
Study: NCT02086643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroclavicular block
Description: Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
Study: NCT02535572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEAST
Description: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
Study: NCT02806076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tumor puncture RFA arm
Description: Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode.
Study: NCT02887001

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist consultation
Study: NCT03542799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR IL12 CART
Description: EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
Study: NCT00128388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFPP
Description: Psychoanalytic Psychotherapy for panic disorder
Study: NCT02535572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RUL UB
Description: This is right unilateral ultrabrief ECT, the standard of care.
Study: NCT05779371

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated-based Laughing Qigong Program
Description: The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
Study: NCT00742664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: The subject will not receive active treatment during this interval.
Study: NCT03948477

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matched placebo
Study: NCT01174433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tryton
Description: Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
Study: NCT02973880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NETILDEX™ ophthalmic gel
Description: 1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NETILDEX™ eye drops solution
Description: 1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery.
Study: NCT01476202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: nicotine in the form of a mouth strip, lozenge and gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: nicotine in the form of a mouth strip, lozenge and gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: nicotine in the form of a mouth strip, lozenge and gum
Study: NCT03048383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA Injectable Product
Description: Administered to treat facial synkinesis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA Injectable Product
Description: Administered to treat facial synkinesis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumtoxin A Injectable Product
Description: Administered to treat facial synkinesis
Study: NCT01989208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SG1002
Description: 200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
Study: NCT03118908

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amberen
Description: Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smart B
Description: Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to Amberen and Smart B capsules.
Study: NCT03587285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcm+ Goserelin acetate+ Bicalutamide
Description: Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcm+Goserelin acetate+Abiraterone acetate
Description: Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
Study: NCT05577520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor augmentation
Study: NCT03619057

Intervention type: OTHER
Intervention: General anesthesia with laryngeal mask i-gel
Description: General anesthesia with laryngeal mask i-gel

Intervention type: OTHER
Intervention: General anesthesia with laryngeal mask i-gel
Description: General anesthesia with laryngeal mask i-gel
Study: NCT00670943

Intervention type: OTHER
Intervention: Platelet function testing

Intervention type: OTHER
Intervention: Platelet function testing
Study: NCT00993226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 1a
Description: 5.0 ml
Study: NCT03928197

Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouchTMNIBP, Vivisol, Belgium
Description: Continous measurement of blood pressure, heart rate and saturation
Study: NCT03651947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
Study: NCT03433781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).
Study: NCT00110994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1
Study: NCT02002702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01845714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross Linking

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross Linking combined with topoguided PRK
Study: NCT00486447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 64 Channel VCT
Description: cardiac CT angiography exam
Study: NCT00128388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Applied Relaxation Training
Study: NCT01816607

Intervention type: PROCEDURE
Intervention: new functional magnetic resonance imaging (MRI) protocols
Description: diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
Study: NCT04709887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound treatment
Description: According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
Study: NCT00993226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 1b
Description: 5.0 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 1c
Description: 40 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 2a
Description: 7.5 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 2b
Description: 7.5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 2c
Description: 40 ml